Edition:
United States

Integra LifeSciences Holdings Corp (IART.OQ)

IART.OQ on NASDAQ Stock Exchange Global Select Market

64.53USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$64.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
223,415
52-wk High
$65.29
52-wk Low
$43.04

Chart for

About

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including... (more)

Overall

Beta: 0.65
Market Cap(Mil.): $5,286.08
Shares Outstanding(Mil.): 81.84
Dividend: --
Yield (%): --

Financials

  IART.OQ Industry Sector
P/E (TTM): 45.52 39.42 32.59
EPS (TTM): 1.42 -- --
ROI: 4.72 14.34 12.60
ROE: 12.18 17.22 14.49

BRIEF-Integra Lifesciences Prices Public Offering Of Common Stock

* INTEGRA LIFESCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK

May 09 2018

BRIEF-Integra LifeSciences Announces Proposed Public Offering Of Common Stock

* INTEGRA LIFESCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

May 09 2018

BRIEF-Integra Lifesciences Announces Amendment And Extension Of Credit Facility

* INTEGRA LIFESCIENCES ANNOUNCES AMENDMENT AND EXTENSION OF CREDIT FACILITY

May 07 2018

BRIEF-Integra Lifesciences Reports Q1 Adjusted Earnings Per Share $0.58

* INTEGRA LIFESCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Apr 25 2018

BRIEF-Integra LifeSciences Says CEO's 2017 Compensation Was $7.1 Mln

* INTEGRA LIFESCIENCES HOLDINGS CORP SAYS CEO PETER J. ARDUINI'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $7 MILLION IN 2016 – SEC FILING ‍​ Source: (https://bit.ly/2HdNFnd) Further company coverage:

Apr 06 2018

BRIEF-Integra Lifesciences Holdings Reports Q4 EPS Of $0.56

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Integra Lifesciences Q4 Adjusted Earnings Per Share $0.64

* INTEGRA LIFESCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Integra Lifesciences Announces Preliminary Q4 Earnings Per Share View $0.55, Revenue View $351.0

* - ‍ORGANIC REVENUE GROWTH IN Q4 IS EXPECTED TO BE ABOUT 5.5%, ABOVE COMPANY'S IMPLIED GUIDANCE OF ABOUT 4%​

Jan 08 2018

BRIEF-Integra Lifesciences Holdings Corp ‍Reaffirms 2017 Financial Guidance As Provided On Oct 26, 2017​

* - ‍REAFFIRMING 2017 FINANCIAL GUIDANCE AS PROVIDED ON OCTOBER 26, 2017​

Dec 11 2017

BRIEF-Capital Research Global Investors Reports 11.1 Pct Passive Stake In Integra Lifesciences As Of Nov 30

* CAPITAL RESEARCH GLOBAL INVESTORS REPORTS 11.1 PERCENT PASSIVE STAKE IN INTEGRA LIFESCIENCES HOLDINGS CORP AS OF NOVEMBER 30 - SEC FILING Source text: (http://bit.ly/2jb88l1) Further company coverage:

Dec 08 2017

Earnings vs. Estimates